Boston's NeuroBo to use bruised Gemphire to make Nasdaq debut
A battered Gemphire will be put out of its misery by Boston-based biotech NeuroBo Pharmaceuticals, which is reverse merging with the Michigan drug developer to make its leap onto the Nasdaq.
Gemphire, which went public three years ago, had acquired its lead (and only) drug — gemcabene — from Pfizer to take it forward in cardio and liver diseases. So far that bet has frustrated the company and its shareholders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
